Form 4 for CAMP Camp4 Therapeutics Corp
Accepted 2024-10-15 00:00:00 ET · period of report 2024-10-15 · accession 0001104659-24-108699 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-15 | 2024-10-15 | CAMP | Mandel-Brehm Josh | CEO, Dir | C - Cnv Deriv | — | +605 | 272.4K | +0.2% | — |
| D | 2024-10-15 | 2024-10-15 | CAMP | Mandel-Brehm Josh | CEO, Dir | C - Cnv Deriv | — | -6,791 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-15 | C | A | 605 | — | 272,357 | D | — | — | (F1) On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. |
| 2 | Derivative | Series B Preferred Stock | 2024-10-15 | C | D | 6,791 | — | 0 | D | — · — to — | 605 Common Stock | (F1) On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. |